File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Adiponectin and cardiovascular health: An update
  • Basic View
  • Metadata View
  • XML View
TitleAdiponectin and cardiovascular health: An update
 
AuthorsHui, X1
Lam, KSL1
Vanhoutte, PM1
Xu, A1
 
Keywordsadipokine
adiponectin
cardiovascular disease
endothelial dysfunction
inflammation
obesity
vasculature
 
Issue Date2012
 
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0007-1188&site=1
 
CitationBritish Journal of Pharmacology, 2012, v. 165 n. 3, p. 574-590 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1476-5381.2011.01395.x
 
AbstractThe global epidemic of obesity is accompanied by an increased prevalence of cardiovascular disease (CVD), in particular stroke and heart attack. Dysfunctional adipose tissue links obesity to CVD by secreting a multitude of bioactive lipids and pro-inflammatory factors (adipokines) with detrimental effects on the cardiovascular system. Adiponectin is one of the few adipokines that possesses multiple salutary effects on insulin sensitivity and cardiovascular health. Clinical investigations have identified adiponectin deficiency (hypoadiponectinaemia) as an independent risk factor for CVD. In animals, elevation of plasma adiponectin by either pharmacological or genetic approaches alleviates obesity-induced endothelial dysfunction and hypertension, and also prevents atherosclerosis, myocardial infarction and diabetic cardiomyopathy. Furthermore, many therapeutic benefits of the peroxisome-proliferator activated receptor gamma agonists, the thiazolidinediones, are mediated by induction of adiponectin. Adiponectin protects cardiovascular health through its vasodilator, anti-apoptotic, anti-inflammatory and anti-oxidative activities in both cardiac and vascular cells. This review summarizes recent findings in the understanding of the physiological role and clinical relevance of adiponectin in cardiovascular health, and in the identification of the receptor and postreceptor signalling events that mediate the cardiovascular actions of adiponectin. It also discusses adiponectin-targeted drug discovery strategies for treating obesity, diabetes and CVD. Linked Articles This article is part of a themed section on Fat and Vascular Responsiveness. To view the other articles in this section visit © 2011 The British Pharmacological Society.
 
ISSN0007-1188
2013 Impact Factor: 4.990
2013 SCImago Journal Rankings: 2.253
 
DOIhttp://dx.doi.org/10.1111/j.1476-5381.2011.01395.x
 
PubMed Central IDPMC3315032
 
ISI Accession Number IDWOS:000298953100004
Funding AgencyGrant Number
Research Grants Council of Hong KongHKU 2/07C
HKU4/CRF/10
Funding Information:

This work was supported by collaborative research fund (HKU 2/07C and HKU4/CRF/10) from the Research Grants Council of Hong Kong.

 
ReferencesReferences in Scopus
 
GrantsVascular dysfunction in obesity and diabetes: from risk prediction to therapeutic intervention
A Multi-disciplinary Approach to Investigate Vascular Dysfunction in Obesity and Diabetes: From Molecular Mechanism to Therapeutic Intervention
 
DC FieldValue
dc.contributor.authorHui, X
 
dc.contributor.authorLam, KSL
 
dc.contributor.authorVanhoutte, PM
 
dc.contributor.authorXu, A
 
dc.date.accessioned2012-05-23T05:48:30Z
 
dc.date.available2012-05-23T05:48:30Z
 
dc.date.issued2012
 
dc.description.abstractThe global epidemic of obesity is accompanied by an increased prevalence of cardiovascular disease (CVD), in particular stroke and heart attack. Dysfunctional adipose tissue links obesity to CVD by secreting a multitude of bioactive lipids and pro-inflammatory factors (adipokines) with detrimental effects on the cardiovascular system. Adiponectin is one of the few adipokines that possesses multiple salutary effects on insulin sensitivity and cardiovascular health. Clinical investigations have identified adiponectin deficiency (hypoadiponectinaemia) as an independent risk factor for CVD. In animals, elevation of plasma adiponectin by either pharmacological or genetic approaches alleviates obesity-induced endothelial dysfunction and hypertension, and also prevents atherosclerosis, myocardial infarction and diabetic cardiomyopathy. Furthermore, many therapeutic benefits of the peroxisome-proliferator activated receptor gamma agonists, the thiazolidinediones, are mediated by induction of adiponectin. Adiponectin protects cardiovascular health through its vasodilator, anti-apoptotic, anti-inflammatory and anti-oxidative activities in both cardiac and vascular cells. This review summarizes recent findings in the understanding of the physiological role and clinical relevance of adiponectin in cardiovascular health, and in the identification of the receptor and postreceptor signalling events that mediate the cardiovascular actions of adiponectin. It also discusses adiponectin-targeted drug discovery strategies for treating obesity, diabetes and CVD. Linked Articles This article is part of a themed section on Fat and Vascular Responsiveness. To view the other articles in this section visit © 2011 The British Pharmacological Society.
 
dc.description.naturelink_to_OA_fulltext
 
dc.identifier.citationBritish Journal of Pharmacology, 2012, v. 165 n. 3, p. 574-590 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1476-5381.2011.01395.x
 
dc.identifier.doihttp://dx.doi.org/10.1111/j.1476-5381.2011.01395.x
 
dc.identifier.epage590
 
dc.identifier.hkuros199771
 
dc.identifier.hkuros213324
 
dc.identifier.isiWOS:000298953100004
Funding AgencyGrant Number
Research Grants Council of Hong KongHKU 2/07C
HKU4/CRF/10
Funding Information:

This work was supported by collaborative research fund (HKU 2/07C and HKU4/CRF/10) from the Research Grants Council of Hong Kong.

 
dc.identifier.issn0007-1188
2013 Impact Factor: 4.990
2013 SCImago Journal Rankings: 2.253
 
dc.identifier.issue3
 
dc.identifier.pmcidPMC3315032
 
dc.identifier.pmid21457225
 
dc.identifier.scopuseid_2-s2.0-81855177709
 
dc.identifier.spage574
 
dc.identifier.urihttp://hdl.handle.net/10722/146888
 
dc.identifier.volume165
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0007-1188&site=1
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofBritish Journal of Pharmacology
 
dc.relation.projectVascular dysfunction in obesity and diabetes: from risk prediction to therapeutic intervention
 
dc.relation.projectA Multi-disciplinary Approach to Investigate Vascular Dysfunction in Obesity and Diabetes: From Molecular Mechanism to Therapeutic Intervention
 
dc.relation.referencesReferences in Scopus
 
dc.rightsBritish Journal of Pharmacology. Copyright © John Wiley & Sons Ltd.
 
dc.subject.meshAdiponectin - metabolism
 
dc.subject.meshBiological Markers
 
dc.subject.meshCardiovascular Diseases - metabolism - prevention and control
 
dc.subject.meshReceptors, Adiponectin - metabolism
 
dc.subject.meshThiazolidinediones - therapeutic use
 
dc.subjectadipokine
 
dc.subjectadiponectin
 
dc.subjectcardiovascular disease
 
dc.subjectendothelial dysfunction
 
dc.subjectinflammation
 
dc.subjectobesity
 
dc.subjectvasculature
 
dc.titleAdiponectin and cardiovascular health: An update
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Hui, X</contributor.author>
<contributor.author>Lam, KSL</contributor.author>
<contributor.author>Vanhoutte, PM</contributor.author>
<contributor.author>Xu, A</contributor.author>
<date.accessioned>2012-05-23T05:48:30Z</date.accessioned>
<date.available>2012-05-23T05:48:30Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>British Journal of Pharmacology, 2012, v. 165 n. 3, p. 574-590</identifier.citation>
<identifier.issn>0007-1188</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/146888</identifier.uri>
<description.abstract>The global epidemic of obesity is accompanied by an increased prevalence of cardiovascular disease (CVD), in particular stroke and heart attack. Dysfunctional adipose tissue links obesity to CVD by secreting a multitude of bioactive lipids and pro-inflammatory factors (adipokines) with detrimental effects on the cardiovascular system. Adiponectin is one of the few adipokines that possesses multiple salutary effects on insulin sensitivity and cardiovascular health. Clinical investigations have identified adiponectin deficiency (hypoadiponectinaemia) as an independent risk factor for CVD. In animals, elevation of plasma adiponectin by either pharmacological or genetic approaches alleviates obesity-induced endothelial dysfunction and hypertension, and also prevents atherosclerosis, myocardial infarction and diabetic cardiomyopathy. Furthermore, many therapeutic benefits of the peroxisome-proliferator activated receptor gamma agonists, the thiazolidinediones, are mediated by induction of adiponectin. Adiponectin protects cardiovascular health through its vasodilator, anti-apoptotic, anti-inflammatory and anti-oxidative activities in both cardiac and vascular cells. This review summarizes recent findings in the understanding of the physiological role and clinical relevance of adiponectin in cardiovascular health, and in the identification of the receptor and postreceptor signalling events that mediate the cardiovascular actions of adiponectin. It also discusses adiponectin-targeted drug discovery strategies for treating obesity, diabetes and CVD. Linked Articles This article is part of a themed section on Fat and Vascular Responsiveness. To view the other articles in this section visit &#169; 2011 The British Pharmacological Society.</description.abstract>
<language>eng</language>
<publisher>John Wiley &amp; Sons Ltd. The Journal&apos;s web site is located at http://www.wiley.com/bw/journal.asp?ref=0007-1188&amp;site=1</publisher>
<relation.ispartof>British Journal of Pharmacology</relation.ispartof>
<rights>British Journal of Pharmacology. Copyright &#169; John Wiley &amp; Sons Ltd.</rights>
<subject>adipokine</subject>
<subject>adiponectin</subject>
<subject>cardiovascular disease</subject>
<subject>endothelial dysfunction</subject>
<subject>inflammation</subject>
<subject>obesity</subject>
<subject>vasculature</subject>
<subject.mesh>Adiponectin - metabolism</subject.mesh>
<subject.mesh>Biological Markers</subject.mesh>
<subject.mesh>Cardiovascular Diseases - metabolism - prevention and control</subject.mesh>
<subject.mesh>Receptors, Adiponectin - metabolism</subject.mesh>
<subject.mesh>Thiazolidinediones - therapeutic use</subject.mesh>
<title>Adiponectin and cardiovascular health: An update</title>
<type>Article</type>
<description.nature>link_to_OA_fulltext</description.nature>
<identifier.doi>10.1111/j.1476-5381.2011.01395.x</identifier.doi>
<identifier.pmid>21457225</identifier.pmid>
<identifier.pmcid>PMC3315032</identifier.pmcid>
<identifier.scopus>eid_2-s2.0-81855177709</identifier.scopus>
<identifier.hkuros>199771</identifier.hkuros>
<identifier.hkuros>213324</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-81855177709&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>165</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>574</identifier.spage>
<identifier.epage>590</identifier.epage>
<identifier.isi>WOS:000298953100004</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<relation.project>Vascular dysfunction in obesity and diabetes: from risk prediction to therapeutic intervention</relation.project>
<relation.project>A Multi-disciplinary Approach to Investigate Vascular Dysfunction in Obesity and Diabetes: From Molecular Mechanism to Therapeutic Intervention</relation.project>
<bitstream.url>http://hub.hku.hk/bitstream/10722/146888/1/re01.htm</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong